{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:56:59Z","timestamp":1781672219689,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Efficient and safe mobilisation of haematopoietic stem cells is essential for successful autologous haematopoietic stem cell transplantation (ASCT). Although pegylated recombinant human granulocyte colony stimulating factor, (PEG-rhG-CSF) is widely used for chemotherapy-induced neutropenia, comparative data on its use with high-dose etoposide (VP-16) for mobilisation remain scarce. In particular, direct comparisons between mecapegfilgrastim and recombinant human G-CSF (rhG-CSF) in this setting are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, we analysed the efficacy and safety of high-dose VP-16 (1.6 g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) combined with PEG-rhG-CSF (100 \u03bcg\/kg) versus high-dose VP-16 (1.6 g\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) combined with rhG-CSF (10 \u03bcg\/kg\/d) for stem cell mobilisation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-one patients were included: 32 received VP-16+PEG-rhG-CSF and 39 received VP-16+rhG-CSF. Baseline characteristics were comparable. Mobilisation success exceeded 90% in both groups. However, the PEG-rhG-CSF group achieved a significantly higher total CD34\n                      <jats:sup>+<\/jats:sup>\n                      cell yield, a greater proportion of optimal mobilisers, and a higher first-day collection success rate. Fewer number of apheresis and a shorter mobilisation duration were observed in this group. The incidence of febrile infection was significantly lower with PEG-rhG-CSF, whereas platelet transfusion requirements and engraftment kinetics were similar between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-dose VP-16 combined with PEG-rhG-CSF demonstrated superior efficacy, safety, and procedural efficiency compared with high-dose VP-16 plus rhG-CSF. These findings suggest that this regimen represents a promising and potentially preferable alternative for haematopoietic stem cell mobilisation in patients with multiple myeloma or lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1879386","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:48:21Z","timestamp":1781671701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Yiming","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Hematology, Anhui Public Health Clinical Center","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Hematology, Anhui Public Health Clinical Center","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Hematology, Anhui Public Health Clinical Center","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Hematology, Anhui Public Health Clinical Center","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]},{"name":"Department of Hematology, Anhui Public Health Clinical Center","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tmrv.2018.11.003","article-title":"Peripheral blood or bone marrow stem cells? Practical considerations in hematopoietic stem cell transplantation","volume":"33","author":"Amouzegar","year":"2018","journal-title":"Transfus Med Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.blre.2014.01.001","article-title":"Advances in stem cell mobilization","volume":"28","author":"Hopman","year":"2014","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/cancers15030608","article-title":"Poor mobilizers in lymphoma but not myeloma patients had significantly poorer progression-free survival after autologous stem cell transplantation: results of a large retrospective, single-center observational study","volume":"15","author":"Steiner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102594","article-title":"Evolution of conditioning regimens prior to autologous stem cell transplantation in lymphoma patients","volume":"63","author":"Tian","year":"2025","journal-title":"Transl Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.003","article-title":"Stem cell mobilization yields with daratumumab (Dara) and lenalidomide (Len)-containing quadruplet induction therapy in patients with newly diagnosed multiple myeloma (NDMM): a real-world experience at 2 institutes","volume":"25","author":"Varga","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2148","article-title":"PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization","volume":"33","author":"Rossi","year":"2014","journal-title":"Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.11.002","article-title":"Diabetes mellitus as a poor mobilizer condition","volume":"32","author":"Fadini","year":"2017","journal-title":"Blood Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05170-0","article-title":"Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments","volume":"102","author":"Wei","year":"2023","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.4081\/hr.2016.6319","article-title":"The high effect of chemomobilization with high-dose etopside + granulocyte-colony stimulating factor in autologous hematopoietic peripheral blood stem cell transplantation: a single center experience","volume":"8","author":"G\u00fcner","year":"2016","journal-title":"Hematol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.012","article-title":"High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma","volume":"20","author":"Hyun","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00836-y","article-title":"Mecapegfilgrastim in chemotherapy-induced neutropenia: a profile of its use in China","volume":"39","author":"Al-Salama","year":"2019","journal-title":"Clin Drug Investig"},{"key":"B17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim","volume":"50","author":"Yang","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03177-9","article-title":"Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"114","author":"Danylesko","year":"2021","journal-title":"Int J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754366","article-title":"Cost-effectiveness analysis of PEG-rhG-CSF as primary prophylaxis to chemotherapy-induced neutropenia in women with breast cancer in China: results based on real-world data","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14993","article-title":"Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients","volume":"59","author":"Partanen","year":"2018","journal-title":"Transfusion"},{"key":"B21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/s12885-023-11197-3","article-title":"A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic Malignancies","volume":"23","author":"Wen","year":"2023","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.825550","article-title":"High efficacy of stem cell mobilization with etoposide+cytarabine plus G-CSF in patients with multiple myeloma","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12266","article-title":"Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review","volume":"92","author":"Ozkan","year":"2014","journal-title":"Eur J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.01.014","article-title":"Application of pegylated recombinant human granulocyte colony stimulating factor in mobilization of autologous peripheral blood stem cells","volume":"42","author":"Wang","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03800-0","article-title":"Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma","volume":"99","author":"Ding","year":"2020","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21550","article-title":"Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis","volume":"32","author":"Kuan","year":"2017","journal-title":"J Clin Apher"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621935","article-title":"Allogeneic hematopoietic stem cell transplantation mobilized with pegylated granulocyte colony-stimulating factor ameliorates severe acute graft-versus-host disease through enrichment of monocytic myeloid-derived suppressor cells in the graft: a real world experience","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12081","article-title":"Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor","volume":"93","author":"Bruns","year":"2008","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jca.70091","article-title":"Safety and efficacy of cyclophosphamide with dual mecapegfilgrastim and on-demand plerixafor for salvage mobilization in patients with initial mobilization failure: a retrospective cohort","volume":"41","author":"Huang","year":"2026","journal-title":"J Clin Apher"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15507","article-title":"A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF)","volume":"89","author":"Huang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.10.006","article-title":"The efficacy research of prophylactic PEG-rhG-CSF in preventing neutropenia in early-stage breast cancer patients treated with docetaxel-based chemotherapy: a retrospective analysis","volume":"47","author":"Xing","year":"2024","journal-title":"Clin Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06183-7","article-title":"PEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia","volume":"104","author":"Jin","year":"2025","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1879386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:48:27Z","timestamp":1781671707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1879386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1879386"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1879386","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1879386"}}